ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$11.34 USD
-0.32 (-2.74%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $11.31 -0.03 (-0.26%) 7:56 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.34 USD
-0.32 (-2.74%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $11.31 -0.03 (-0.26%) 7:56 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
ARS Pharmaceuticals, Inc. (SPRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's Why
by Zacks Equity Research
ARS Pharmaceuticals, Inc. (SPRY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
ARS Pharmaceuticals (SPRY) Down on CRL for Nasal Spray
by Zacks Equity Research
ARS Pharmaceuticals, Inc. (SPRY) plunges on a surprise CRL by the FDA for its nasal spray curated for allergic reactions.
Biotech Stock Roundup: GSK's Drug Approval, MRNA's Vaccine News, PTCT & SPRY Down
by Zacks Equity Research
Regulatory updates from GSK and Moderna (MRNA) are in focus in the biotech sector.
ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
by Zacks Equity Research
ARS Pharmaceuticals (SPRY) gains as it gets favorable votes from the FDA advisory committee for epinephrine spray to treat severe allergic reactions.
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML
Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CSML
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CSML